More High-Cost Therapies Are Coming… But a New Partner is Keeping Us One Step Ahead
With approval rates of high-cost CAR T-cell and gene therapies escalating, the time has come for employers to get proactive about managing their potential risk appropriately. CAR T-cell and gene therapies are designed to treat extremely rare diseases such as blood disorders, cancers, and metabolic and neurogenerative diseases by transferring live cells into the body […]